Indications for ZERBAXA:
Susceptible complicated intra-abdominal infections (cIAI) in combination with metronidazole, complicated urinary tract infections (cUTI), including pyelonephritis, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
Give by IV infusion over 1hr. ≥18yrs (CrCl >50mL/min): cIAI: 1.5g every 8hrs for 4–14 days with IV metronidazole 500mg every 8hrs; cUTI: 1.5g every 8hrs for 7 days; HABP/VABP: 3g every 8hrs for 8–14 days. Renal impairment: cIAI, cUTI (CrCl 30–50mL/min): 750mg every 8hrs; (CrCl 15–29mL/min): 375mg every 8hrs; ESRD on hemodialysis: 750mg loading dose, followed by 150mg maintenance dose every 8hrs for remainder of treatment (give on dialysis days). HABP/VABP (CrCl 30–50mL/min): 1.5g every 8hrs; (CrCl 15–29mL/min): 750mg every 8hrs; ESRD on hemodialysis: 2.25g loading dose, followed by 450mg maintenance dose every 8hrs for remainder of treatment (give on dialysis days).
<18yrs: not established.
Cephalosporin, penicillin, or other beta-lactam allergy.
Discontinue if serious hypersensitivity reactions occur. Monitor CrCl at least daily in those with changing renal function and adjust dose. Elderly. Pregnancy. Nursing mothers.
Cephalosporin + beta-lactamase inhibitor.
Nausea, diarrhea, headache, pyrexia, increased transaminases, renal impairment/failure; C. difficile-associated diarrhea, anaphylaxis.
Generic Drug Availability: